Ezetimibe is a cholesterol-lowering medication that works differently from statins. Instead of blocking cholesterol production in the liver, it blocks cholesterol absorption in the small intestine. It’s taken as a single 10 mg tablet once daily, with or without food, and is used most often alongside a statin when that statin alone isn’t bringing LDL (“bad”) cholesterol down far enough.
How Ezetimibe Lowers Cholesterol
Your small intestine has a specific protein on the surface of its cells that acts as a gatekeeper, pulling cholesterol from food and bile into the body. Ezetimibe binds to this protein and blocks it. Without that gateway functioning, less dietary and recycled cholesterol makes it into your bloodstream.
On its own, ezetimibe lowers LDL cholesterol by about 18%. That’s modest compared to a statin, which is why it’s rarely prescribed as a first-line treatment. Its real value shows up in combination: adding ezetimibe to a statin drops LDL an additional 15% to 20% beyond what the statin achieves alone. Because statins and ezetimibe work through completely different pathways, they complement each other rather than overlap.
Approved Uses
The FDA has approved ezetimibe for several specific situations, all related to elevated cholesterol or related plant sterols:
- Primary hyperlipidemia in adults: Used in combination with a statin, or alone when a statin isn’t an option, to reduce elevated LDL cholesterol. This includes people with the inherited condition heterozygous familial hypercholesterolemia.
- Pediatric familial hypercholesterolemia: Approved in combination with a statin for children 10 and older with the heterozygous form, and for children 10 and older with the more severe homozygous form.
- Mixed hyperlipidemia: Used with fenofibrate in adults who have elevations in multiple types of blood fats, not just LDL.
- Homozygous sitosterolemia: A rare inherited condition where the body absorbs too much plant sterol. Ezetimibe is approved for adults and children 9 and older to reduce those elevated sterol levels.
When Doctors Typically Add It
In practice, ezetimibe enters the picture when a statin at the highest tolerable dose still isn’t enough. The 2026 ACC/AHA cholesterol guidelines lay out specific scenarios. For people who already have cardiovascular disease (meaning they’ve had a heart attack, stroke, or documented artery blockage), the LDL goal is below 55 mg/dL. If a statin alone doesn’t get there, ezetimibe is a recommended addition.
For people with very high cholesterol (LDL at or above 190 mg/dL) who haven’t yet had a cardiovascular event, the threshold depends on other risk factors. Someone with a confirmed genetic cholesterol disorder or additional risk factors has a target below 70 mg/dL, and ezetimibe is recommended if a statin doesn’t reach it. Even in primary prevention, where someone has a 10% or greater estimated risk of a cardiovascular event over the next decade, guidelines support adding ezetimibe when statin therapy alone falls short of a 70 mg/dL goal.
Ezetimibe is also used by people who can’t tolerate statins at all, though the LDL reduction from ezetimibe alone is smaller. In those cases, it may be paired with other non-statin medications.
What to Expect: Dosing and Timing
Ezetimibe comes in one strength: 10 mg. You take it once a day, and it doesn’t matter whether you take it with a meal or on an empty stomach. There’s no dose titration or adjustment period. If you’re also taking a bile acid sequestrant (a different type of cholesterol medication that binds bile in the gut), timing matters: take ezetimibe at least 2 hours before or 4 hours after the sequestrant, because otherwise the sequestrant can trap ezetimibe and reduce its effectiveness.
Side Effects
Ezetimibe is generally well tolerated. The most commonly reported side effects are mild: diarrhea, sore throat, runny nose, sneezing, and joint or back pain. These overlap significantly with what people on placebo report in clinical trials, which is part of why ezetimibe has a reputation as an easy medication to take.
Serious reactions are uncommon. Signs that warrant prompt medical attention include skin rash or hives, swelling of the face or throat, unusual fatigue, loss of appetite, pain in the upper right abdomen, or yellowing of the skin or eyes. Those last few symptoms can signal liver problems, which is why people with active liver disease should discuss this with their doctor before starting ezetimibe. Muscle pain or weakness, while rare with ezetimibe alone, can occur more frequently when it’s combined with a statin.
Notable Drug Interactions
Beyond the timing issue with bile acid sequestrants, a few interactions are worth knowing about. Cyclosporine, an immune-suppressing medication used after organ transplants and for certain autoimmune conditions, can increase ezetimibe levels in the blood and vice versa. People taking both need monitoring.
Combining ezetimibe with fibrates (another class of lipid-lowering drugs) requires some caution. Both ezetimibe and fibrates increase the amount of cholesterol excreted into bile, which can raise the risk of gallstones. Fenofibrate is the one fibrate specifically approved for use alongside ezetimibe. Other fibrates in combination with ezetimibe are not recommended.
Ezetimibe should not be taken during pregnancy. Women who become pregnant while on the medication should stop taking it and contact their healthcare provider.
Where Ezetimibe Fits in Cholesterol Management
Statins remain the foundation of cholesterol treatment for most people because they have decades of evidence showing they reduce heart attacks and strokes. Ezetimibe occupies a well-defined second-line role. It’s the most common next step when a statin alone isn’t doing enough, partly because it’s effective, well tolerated, available as a generic, and simple to use. For the smaller number of people who can’t take statins at all, it offers a modest but meaningful LDL reduction on its own. In people with the rare condition sitosterolemia, it’s one of the few medications that directly addresses the underlying problem of excess sterol absorption.